CD274 and non-small cell lung carcinoma: From 2011 to 2021, FDA approvals of 15 immune checkpoint inhibitors were linked with companion PDL1 testing including non-small cell lung cancer (NSCLC) (N = 7), bladder cancer (N = 3), triple-negative breast cancer (N = 2), cervical cancer (N = 2) and gastric cancer (N = 1).